Luxturna, which just got recommended for an FDA nod, can potentially reverse blindness using a manmade virus to ‘infect’ the eye.
Katherine is a freelance writer and analyst based in Vancouver, Canada. She is a member of the Council of Healthcare Advisors for the Gerson Lehrman Group in New York, advising investment analysts on biotechnology. She has also been interviewed by The New York Times, Business Week, and Forbes regarding reports she has written, and has consulted for the United Nations regarding genetics and radiation. Katherine received her BSc in Biochemistry from Harvard University, and did her doctoral training in Molecular Pathology at the University of Washington in Seattle. In addition to publishing several scientific papers in medical genetics, she is also a prize-winning poet.